US equities
|
NVDA
$239.82
▲+2.51%
SPCX
$169.35
▲+6.54%
MU
$1,060.56
▼-1.33%
TSLA
$380.89
▲+2.78%
SNDK
$1,691.54
▼-1.65%
MSFT
$528.35
▲+2.09%
INTC
$116.37
▼-2.48%
META
$743.05
▲+2.06%
NVDA
$239.82
▲+2.51%
SPCX
$169.35
▲+6.54%
MU
$1,060.56
▼-1.33%
TSLA
$380.89
▲+2.78%
SNDK
$1,691.54
▼-1.65%
MSFT
$528.35
▲+2.09%
INTC
$116.37
▼-2.48%
META
$743.05
▲+2.06%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
NewAmsterdam Pharma Company N.V. - Warrant
(NQ:
NAMSW
)
12.00
-0.65 (-5.14%)
Delayed Quote
Updated: 10:22 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NewAmsterdam Pharma Company N.V. - Warrant
< Previous
1
2
3
4
Next >
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
November 13, 2023
From
NewAmsterdam Pharma N.V
Via
GlobeNewswire
NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer
October 23, 2023
From
NewAmsterdam Pharma N.V
Via
GlobeNewswire
NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation
September 21, 2023
From
NewAmsterdam Pharma N.V
Via
GlobeNewswire
NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference
September 20, 2023
From
NewAmsterdam Pharma N.V
Via
GlobeNewswire
NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer
August 14, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights
August 07, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease
July 25, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares
June 09, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares
June 06, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary Shares
June 06, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients
June 05, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023
June 03, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Present at Jefferies Healthcare Conference
May 31, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023
May 23, 2023
NewAmsterdam to review data on webcast conference call on June 5, 2023 at 8:00 a.m. ET
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights
May 08, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
April 24, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors
April 03, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update
March 31, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Present at Cowen 43rd Annual Health Care Conference
March 01, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Present at the SVB Securities Global BioPharma Conference
February 09, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
NewAmsterdam Pharma Appoints John W. Smither to its Board of Directors
February 06, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy
January 17, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
NewAmsterdam Announces Appointment of David Topper as Chief Financial Officer
December 19, 2022
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
